Datopotamab deruxtecan
Daiichi Sankyo · AstraZeneca · DS-1062a · DS-1062
FollowEvery change as it happens, and a Monday email
Trials
33 active
34 in total · 28 in the EU
What this is
- How it works
- TROP2-targeted antibody-drug conjugate
- How it’s given
- “Commercially available Dato-DXd is prescribed and administered to participants according to standard of care”In the company’s words, NCT07357597 on ClinicalTrials.gov
- Tested for
- Non-small Cell Lung Cancer (10 trials), Breast Cancer (7 trials), Urothelial Cancer (3 trials), Non-small Cell Lung Cancer (NSCLC) (2 trials), Metastatic Non Small Cell Lung Cancer (2 trials), Bladder Cancer (2 trials), Endometrial Cancer (2 trials), Gastric Cancer (2 trials) and 22 more
- Main trialPhase 4
- “This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal Growth Factor Receptor-Mutated (EGFRm) non-small cell lung cancer”In the company’s words, NCT07357597 on ClinicalTrials.gov
- Other names
- DS-1062a · DS-1062 · Dato-DXd · Datroway
Other drugs for Non-small Cell Lung Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- CobimetinibRoche · Phase 2/3
- DivarasibRoche · Phase 3
- EntrectinibRoche · Phase 3
Coming up12
- 11 Jan 2027Phase 3 trial completes · ClinicalTrials.gov
- 28 May 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 28 Jul 2027Phase 3 trial completes · ClinicalTrials.gov
- 1 Sep 2027Phase 3 trial completes · ClinicalTrials.gov
- 1 Oct 2027Phase 2 trial completes · ClinicalTrials.gov
- 1 Nov 2027Phase 3 trial completes · ClinicalTrials.gov
- 1 Jan 2028Phase 1 trial completes · ClinicalTrials.gov
- 4 Jan 2028Phase 4 trial completes · ClinicalTrials.gov
- 2 Feb 2028Phase 3 trial completes · ClinicalTrials.gov
- 7 Feb 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 21 Mar 2028Phase 3 trial completes · ClinicalTrials.gov
- 1 Nov 2028Phase 1 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 17 NovNew trial: none to Phase 2 · ClinicalTrials.gov NCT07941609
Trials34
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | 4 Jan 2028 | An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. | |
| Phase 3Active, not recruiting | 10 May 2024 | Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) | |
| Phase 3Active, not recruiting | 24 Jul 2024 | A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) | |
| Phase 3Active, not recruiting | 25 Aug 2025 | A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) | |
| Phase 3Active, not recruiting | 10 Jul 2026 | A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features | |
| Phase 3Active, not recruiting | 11 Jan 2027 | A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | |
| Phase 3Recruiting | 28 Jul 2027 | A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | |
| Phase 3Active, not recruiting | 1 Sep 2027 | A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) | |
| Phase 3Active, not recruiting | 1 Nov 2027 | Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations | |
| Phase 3Recruiting | 2 Feb 2028 | A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer | |
| Phase 3Recruiting | 21 Mar 2028 | Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer | |
| Phase 3Active, not recruiting | 20 Nov 2028 | A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer | |
| Phase 3Recruiting | 29 Jan 2029 | Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations | |
| Phase 3Active, not recruiting | 11 May 2029 | Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) | |
| Phase 3Recruiting | 28 Dec 2029 | Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations | |
| Phase 3Active, not recruiting | 4 Mar 2030 | Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations | |
| Phase 3Recruiting | 11 Sep 2030 | An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC | |
| Phase 2/3Recruiting | 1 Jun 2029 | Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma | |
| Phase 2Active, not recruiting | 6 May 2025 | Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) | |
| Phase 2Recruiting | 1 Oct 2027 | Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | |
| Phase 2Not yet recruiting | 16 Dec 2028 | A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC | |
| Phase 2Recruiting | 6 Apr 2029 | A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) | |
| Phase 2Recruiting | 28 May 2030 | Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer | |
| Phase 1/2Active, not recruiting | 7 Nov 2023 | A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) | |
| Phase 1/2Active, not recruiting | 29 Nov 2024 | A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer | |
| Phase 1/2Active, not recruiting | 28 May 2027 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | |
| Phase 1/2Recruiting | 7 Feb 2028 | Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies | |
| Phase 1/2Recruiting | 4 Dec 2028 | A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors | |
| Phase 1/2Recruiting | 30 Sep 2029 | A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)] | |
| Phase 1Active, not recruiting | 14 Apr 2024 | Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) | |
| Phase 1Active, not recruiting | 4 May 2026 | Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer | |
| Phase 1Active, not recruiting | 1 Jan 2028 | First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) | |
| Phase 1Active, not recruiting | 1 Nov 2028 | A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors | |
| Phase 2Completed | 10 Mar 2023 | Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026